Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.

Parambir S DulaiEmily C L WongWalter ReinischJean Frederic ColombelJohn K MarshallNeeraj Narula

Published in: Inflammatory bowel diseases (2022)

Superiority of VDZ to ADA is dependent on baseline probability of response, and a VDZ-CDST is capable of identifying UC patients most appropriate for VDZ vs ADA.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
systemic lupus erythematosus